April 12, 2016
(Managed Care Magazine) – Within our lifetimes, we may look back at chemotherapy and group it with insulin shock therapy, electric baths, bloodletting, and other barbaric medical practices discredited long ago. Today, advances in identifying biomarkers that may predict who will or won’t respond to a treatment offer vast potential for reducing the use of ineffective or even harmful therapies. These biomarkers, typically genetic (prognostic) or genomic (predictive), are propelling the evolution of precision medicine from pipe dream to work-in-progress to clinical reality.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.